Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Measles
New measles study findings have been reported by researchers at Mayo Clinic
August 13th, 2008
"Patients recruited in virus-based cancer clinical trials and immunocompromised individuals in need of vaccination would profit from viral strains with defined attenuation mechanisms. We generated measles virus (W) strains defective for the expression of either the V protein, a modulator of the innate immune response, or the C protein, which has multiple functions," scientists in the United States report. "The virulence of these strains was compared with that of the parental wild-type MV in a natural host, Macaca mulatta. Skin rash, viremia, and the strength of the innate and adaptive immune responses were characterized in groups of six animals. Replication of V- or...
Source: Vaccine Weekly (2008-08-13)
|
